Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate whether Rebamipide facilitate the healing of inflamed mucosa as an adjuvant regimen in erosive reflux esophagitis (ERE).
Full description
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male/female patients aged 20 to 70 at the time of writing an informed consent.
Subjects who were diagnosed with Erosive Reflux Esophagitis (ERE) using Los Angeles (LA) classification grade A~D, confirmed by endoscopy.
The subjects regardless of presence of ERE symptom (i.e., symptomatic ERE or asymptomatic ERE).
For symptomatic ERE, the subject must have one or more symptoms of the followings: acid regurgitation, heartburn, epigastric pain, cough, hoarseness, globus pharyngis, atypical chest pain.
Subjects who have consented to participate in this clinical study by signing an informed consent form.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
143 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal